Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted againstinterleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis^[1][2].

Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A^[2].
Secukinumab (1 nM, 10 nM, and 100 nM) inhibits IL17A and IL17A/TNF a-induced increase in protein levels of IL6 in human astrocytes^[3].

Liquid

1229022-83-6

苏金单抗；司库奇尤单抗

Please store the product under the recommended conditions in the Certificate of Analysis.